



## **Dr. Irenej Kianicka Joins Chlorion's Team as Director of Pharmacology & Toxicology**

LAVAL, QC, October 15 -- Chlorion Pharma Inc. today announced that Dr. Irenej Kianicka has stepped in as the company's Director of Pharmacology & Toxicology.

In this position, Dr. Kianicka is responsible for heading Chlorion's Department of Pharmacology and Toxicology and its *in vivo* testing facility, and for managing IND-enabling development.

Dr. Jeffrey Coull, Chlorion's President & Acting CEO, emphasized how delighted the company is to welcome Dr. Kianicka, and stressed the timely nature of his appointment: "Above all, Dr. Kianicka is an expert in IND-enabling development, which is very important given the company's recent initiation thereof for CLP290...his insight and guidance have already allowed us to streamline related operations and accelerate the march toward IND qualification".

Prior to joining Chlorion, Dr. Kianicka held senior positions in the safety pharmacology and toxicology departments at several companies, including Shire Biochem, and most recently, at Vertex. Altogether, he brings over 17 years experience in the biopharmaceutical domain to Chlorion.

### About the Company

Chlorion Pharma Inc. is a biopharmaceutical company focused on neurotherapeutics that act via the modulation of chloride in the central nervous system. Presently, the company is developing first-in-class therapeutics for the treatment of neuropathic pain and epilepsy.

For more information, please visit our website at [www.chlorion.com](http://www.chlorion.com).

##